Journal of Bone Oncology最新文献

{"title":"Comparative analysis of X-ray, CT, and MRI images in patients with chondroblastoma in tubular and non-tubular bones","authors":"Xiang Feng ,&nbsp;Yuxiang Fang ,&nbsp;Hanhua Yu ,&nbsp;Zhanqiang Song ,&nbsp;Xiangrong Guo ,&nbsp;Man Yang","doi":"10.1016/j.jbo.2025.100691","DOIUrl":"10.1016/j.jbo.2025.100691","url":null,"abstract":"<div><h3>Objective</h3><div>To compare and analyze the image features of X-ray, computerized tomography (CT), and magnetic resonance imaging (MRI) in patients with chondroblastoma (CB) in tubular and non-tubular bones, to improve the preoperative diagnostic accuracy and follow-up the postoperative recurrence rate.</div></div><div><h3>Methods</h3><div>Sixty-one CB patients confirmed by surgical pathology in our hospital and Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital from August 2013 to March 2024 were included in this study. Their clinical, image, and pathological data were retrospectively collected and analyzed. Clinical data included age and gender. Image data included lesion size, lobulation, distensibility, bone crest, calcification, sclerotic margin, periosteal reaction, soft tissue swelling, fluid level, and aneurysmal bone cyst (ABC). Pathologic data included pathological findings and immunohistochemistry (IHC).</div><div>Results</div><div>The average onset age in tubular bone and non-tubular bone groups was 17.3 ± 5.5 and 25.6 ± 5.7 respectively (<em>p</em> = 0.00). The percentage of distensibility with or without was 37 %, 63 %, 69 % and 31 % (<em>p</em> = 0.01), the percentage of bone crest with or without was 46 %, 54 %, 77 % and 20 % (<em>p</em> = 0.01), and the percentage of fluid level with or without was 17 %, 83 %, 62 % and 38 % in tubular bone and non-tubular bone groups, respectively (<em>p</em> = 0.00). CB was predominantly non-calcified or mottled calcification in patients with lesions less than 12 months and patchy or cloudy calcification in patients with lesions more than 12 months. CB of the calcaneus and talus accounted for 54 % of the CB of the non-tubular bones. There was one case of preoperative malignant lesion and one case of postoperative recurrence.</div></div><div><h3>Conclusion</h3><div>Lesions in CB patients in non-tubular bone are swollen and are prone to form a coarse bone creast and fluid level, and the bone swells even more obviously when CB is combined with ABC. There is a low possibility of malignant transformation and postoperative recurrence in CB patients.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100691"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144168091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The metastatic role of the CXCL10-CXCR3 axis and its therapeutic potential in osteosarcoma","authors":"Benjamin B. Gyau ,&nbsp;Junyan Wang ,&nbsp;Xiang Chen ,&nbsp;Margaret A. Clement ,&nbsp;Zoe D. Man ,&nbsp;Angela M. Major ,&nbsp;Mathew C. Weiser ,&nbsp;Jun Xu ,&nbsp;John Hicks ,&nbsp;Tsz-Kwong Man","doi":"10.1016/j.jbo.2025.100690","DOIUrl":"10.1016/j.jbo.2025.100690","url":null,"abstract":"<div><div>The CXCL10-CXCR3 axis regulates immunity, tumorigenesis, and metastasis in multiple cancers. Yet, its roles in osteosarcoma (OS), the predominant pediatric malignant bone tumor, are not fully defined. Our prior work has shown that elevated serum CXCL10 levels correlate with poor OS prognosis. The current study delves deeper by investigating how CXCL10-mediated CXCR3 signaling influences OS growth and metastatic spread. <em>In vitro</em>, CXCL10 and related CXCR3 ligands (CXCL4, CXCL9, and CXCL11) enhanced OS tumor cell migration. In an orthotopic xenograft mouse model with a newly created CXCR3 knockout (KO) mutant, tumor growth and lung metastasis decreased significantly when compared with the parental cell line. Transfecting the transcript isoform CXCR3A, but not CXCR3B, into KO cells restored metastatic phenotypes in mice, highlighting isoform specificity. Pharmacological CXCR3 inhibition reduced OS cell migration <em>in vitro</em> and metastasis <em>in vivo</em>. Mechanistically, CXCL10 triggered AKT (S473) and PAK1 (S144) phosphorylation in OS cell lines, but not in the KO mutant, implicating the role of these kinases in CXCL10-mediated metastasis. Collectively, our data indicate the CXCL10-CXCR3 axis as a key metastatic driver in OS, suggesting CXCR3 as a viable therapeutic target for treating OS metastasis.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100690"},"PeriodicalIF":3.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144147944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of responsive nano-drug carriers in bone tumor chemotherapy","authors":"Peiyang Cai,&nbsp;Minjie Fan,&nbsp;Pengfei Zheng","doi":"10.1016/j.jbo.2025.100689","DOIUrl":"10.1016/j.jbo.2025.100689","url":null,"abstract":"<div><div>Bone tumors, especially malignant ones, have high mortality and disability rates, and traditional treatment methods have limitations. Responsive nano-drug carriers achieve targeted delivery and controlled release of drugs by precisely responding to the tumor microenvironment or external stimuli, thereby improving drug efficacy and reducing toxic side effects. These carriers, including liposomes, micelles, and nano-gels, can respond to internal stimuli such as pH, redox, enzymes, and hypoxia, as well as external stimuli such as light, magnetic fields, and ultrasound. By optimizing carrier design, significant improvements in drug targeting, bioavailability, and therapeutic effects can be achieved, providing new ideas and methods for the comprehensive treatment of bone tumors.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100689"},"PeriodicalIF":3.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144116310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of comprehensive local therapy on treatment outcomes of non-small cell lung cancer with solitary skeletal oligometastasis","authors":"Jia-nan Jin ,&nbsp;Zheng-bo Song ,&nbsp;Wen-xian Wang ,&nbsp;Yi Li ,&nbsp;Shi-yan Wu","doi":"10.1016/j.jbo.2025.100688","DOIUrl":"10.1016/j.jbo.2025.100688","url":null,"abstract":"<div><h3>Background</h3><div>The oligometastatic status of non-small lung cancer (NSCLC) has been extensively studied over the years owing to its potential significance in long-term survival. Bone is one of the most commonly affected organs in oligometastatic NSCLC. The value of comprehensive local therapy (CLT) for NSCLC with solitary skeletal oligometastasis remains to be established.</div></div><div><h3>Methods</h3><div>Data on NSCLC cases with solitary skeletal oligometastasis were collected retrospectively between August 2008 and March 2022. Kaplan–Meier and Cox regression analyses were performed to assess clinical outcomes.</div></div><div><h3>Results</h3><div>Sixty-seven patients were included in the final analysis, 23 (34.3 %) of whom received CLT. Median progression-free survival (PFS) and overall survival (OS) were 9.9 and 27.1 months for the non-CLT cohort and 18.8 and 46.0 months for the CLT cohort, respectively. In multivariate analysis, CLT emerged as an independent prognostic factor associated with improved PFS (P = 0.031), but had no significant correlation with OS (P = 0.403). Among 23 patients treated with EGFR-TKIs, the CLT group had a median PFS of 46.8 months and a median OS that was not reached, while the non-CLT group had a median PFS of 15.7 months and a median OS of 30.7 months. CLT plus EGFR-TKI significantly improved PFS versus monotherapy (P = 0.023), though OS did not differ significantly (P = 0.095).</div></div><div><h3>Conclusions</h3><div>In NSCLC patients with solitary skeletal oligometastasis, implementation of CLT appeared to positively influence PFS. The combination of EGFR-TKI and CLT was associated with prolonged PFS compared to EGFR-TKI alone, though further validation is needed to confirm its impact on long-term survival.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100688"},"PeriodicalIF":3.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143947301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single Photon Emission Computed Tomography/X-ray Computed Tomography-based radiomics analysis for diagnosis of bone metastases in patients with breast cancer","authors":"Huiyu Su ,&nbsp;Chunwen Ma ,&nbsp;Dongli Sun ,&nbsp;Jianhua Jin","doi":"10.1016/j.jbo.2025.100686","DOIUrl":"10.1016/j.jbo.2025.100686","url":null,"abstract":"<div><h3>Purpose</h3><div>Bones are the most metastatic site for breast cancer (BC), which can cause complications such as pathologic osteolysis, seriously affecting the quality of life of patients. This study intended to investigate the efficacy of Single Photon Emission Computed Tomography/X-ray Computed Tomography (SPECT/CT) in diagnosing bone metastases in BC and to develop a model for predicting the diagnostic effectiveness.</div></div><div><h3>Methods</h3><div>In this study, we enrolled 185 patients with BC who underwent SPECT/CT scanning. The region of interest (ROI) of each SPECT/CT image was demarcated, and the radiomics features were determined from the ROIs and screened for the optimal features signature to construct the radiomics model. Based on clinical characteristics, the clinical model was developed, and the independent predictive factors were discovered through univariate and multivariate COX regression analyses. Additionally, the radiomics nomogram was created through integrating the radiomics score and independent predictive factors. Thereafter, the receiver operating characteristic (ROC) was applied to determine the diagnostic performance of various models.</div></div><div><h3>Results</h3><div>The radiomics model was constructed based on 29 optimal features. The N stage was an independent factor, and the radiomics nomogram was created through integrating the radiomics score and N stage. Among three models, the radiomics nomogram had the highest diagnostic value for BC bone metastasis (AUC: the training set: 0.956 (0.909–1.000); the validation set: 0.936 (0.866–1.000)).</div></div><div><h3>Conclusion</h3><div>Radiomics analysis based on SPECT/CT can effectively diagnose bone metastasis in BC patients, establishing a theoretical foundation for the formulation of personalized treatment options in clinical practice.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100686"},"PeriodicalIF":3.4,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143943662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting lung metastasis in high-grade Osteosarcoma: The role of CTA Signs, with a Focus on vascular wrapping and intratumoral vascular network","authors":"Zhendong Luo ,&nbsp;Tao Ai ,&nbsp;Zhiqiang Liu ,&nbsp;Litong He ,&nbsp;Yanzhen Hou ,&nbsp;Yulin Li ,&nbsp;Ziyan Zhou ,&nbsp;Xinping Shen","doi":"10.1016/j.jbo.2025.100687","DOIUrl":"10.1016/j.jbo.2025.100687","url":null,"abstract":"<div><h3>Objective</h3><div>Osteosarcoma is a highly malignant bone tumor with a high incidence of lung metastases (LM), significantly impacting the 5-year survival rate of patients. This study aims to predict lung metastasis in osteosarcoma based on computed tomography angiography (CTA) signs.</div></div><div><h3>Methods</h3><div>A retrospective study was conducted involving 89 consecutive patients with osteosarcoma. Clinical features and CTA signs, including age, gender, laterality, primary site, type of bone destruction, T stage, periosteal reaction, tumor length, bone marrow involved length, vascular wrapping, and intratumoral vascular network, were evaluated. Univariate and multivariate logistic regression analyses were used to identify risk factors for LM, followed by receiver operating characteristic (ROC) curve analysis.</div></div><div><h3>Results</h3><div>The vascular wrapping and intratumoral vascular network signs were more frequently observed in LM in patients with osteosarcoma (<em>P</em> &lt; 0.05). The intratumoral vascular network remained an independent risk factor in multivariable regression analysis. ROC curve analysis demonstrated that the area under the curve (AUC) of the logistic regression model was 0.804, indicating good predictive accuracy.</div></div><div><h3>Conclusion</h3><div>Preliminary findings suggest that CTA signs, particularly vascular wrapping and the intratumoral vascular network, may have potential utility in predicting lung metastasis (LM) in osteosarcoma patients. The intratumoral vascular network, in particular, was identified as an independent risk factor.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100687"},"PeriodicalIF":3.4,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143931395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of skeletal pain, general symptoms and patient-reported outcome measures and their value in detecting symptomatic progression – An interdisciplinary prospective study in patients with multiple myeloma","authors":"Carlotta Pietsch ,&nbsp;Monika Engelhardt ,&nbsp;Gabriele Ihorst ,&nbsp;Laura Wystrach ,&nbsp;Johannes Jung ,&nbsp;Hagen Schmal ,&nbsp;Andreas Frodl ,&nbsp;Ralph Wäsch ,&nbsp;Evangelos Terpos ,&nbsp;Georg W. Herget","doi":"10.1016/j.jbo.2025.100685","DOIUrl":"10.1016/j.jbo.2025.100685","url":null,"abstract":"<div><div>Delayed diagnosis of multiple myeloma (MM) and progressive disease (PD) can both increase the risk of skeletal complications and do affects patients’ quality of life (QoL). In this prospective study we analyzed skeletal pain, general symptoms and patient-reported outcome measures (PROMs) in patients with MM and their value in detecting symptomatic progression.</div><div>We evaluated 502 patients, 47 with initial diagnosis (ID) of MM and 455 follow-up patients. At ID, 74% reported bone pain, mostly in the spine. General symptoms, particularly fatigue, were present in 89% of the patients. 88/455 (19%) of the follow-up patients experienced PD. Of these, 65% reported skeletal pain and 81% exhibited general symptoms, with fatigue being the most common. PD was suspected and confirmed as the cause of clinical symptoms in 59/88 (67%) and not suspected in 29/88 (33%). Occurrence and character of bone pain and general symptoms differed significantly between patients with and without PD, as did QoL and health-related status. Logistic regression analysis demonstrated that bone pain at night, pain in various locations, pain of known character with occurrence in different location, pain in the chest, pelvis, and thigh as well as fatigue and weight loss were associated with an increased risk of PD.</div><div>In conclusion, bone pain and general symptoms are helpful in identifying both MM and PD. PROMs can aid in the diagnosis of PD through symptom-based patient assessment. Serologic and, especially in the case of skeletal complaints, additional radiologic diagnostics are required to confirm suspected and to detect unexpected PD.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100685"},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143928558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The phosphatase CTDSPL2 promotes proliferation, invasion, metastasis and regorafenib resistance in osteosarcoma","authors":"Guannan Bai ,&nbsp;Shaobo Zhao ,&nbsp;Manli Zhao ,&nbsp;Limiao Chen ,&nbsp;Wenhao Chen","doi":"10.1016/j.jbo.2025.100684","DOIUrl":"10.1016/j.jbo.2025.100684","url":null,"abstract":"<div><div>Osteosarcoma is the most common bone malignancy in children and adolescents. Patients with metastatic and recurrent osteosarcoma have poor prognosis. Regorafenib is a multi-kinase inhibitor recommended as a complement to standard chemotherapy in the treatment of advanced osteosarcoma. The mechanisms associated with regorafenib resistance remains unclear.</div><div>In this study we performed transcriptomics, proteomics and phosphorylated proteomics using regorafenib-treated osteosarcoma cell lines (MG-63, HOS-MNNG for transcriptomics, HOS-MNNG for proteomics and phosphorylated proteomics). After comprehensive multiomics and verification analyses of differentially expressed genes, essential genes for the malignancy of osteosarcoma cells were identified. The effects of essential genes on the proliferation, invasion, and migration of osteosarcoma were determined. The study also evaluated their role in the apoptosis of osteosarcoma cells. The up-regulation of essential genes was determined by immunohistochemistry assays.</div><div>Using comprehensive multiomics and verification analyses we found that the CTDSPL2 gene might play a role in the malignancy and Regorafenib resistance in osteosarcoma. In vitro and clinical specimen assays demonstrated that CTDSPL2 promotes the proliferation, invasion and metastasis of osteosarcoma cells, while inhibiting tumor cell apoptosis.</div><div>In conclusion CTDSPL2 was identified as an essential gene for survival of osteosarcoma cells. Knockdown of CTDSPL2 expression significantly inhibited the proliferation, invasion, and metastasis of osteosarcoma cells, suggesting that it is involved in the formation and development of osteosarcoma tumors. Our data showed that CTDSPL2 is a potential therapeutic target for patients with osteosarcoma.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100684"},"PeriodicalIF":3.4,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143882860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a nomogram for prognosis of bone metastatic disease in patients with esophageal squamous cell carcinoma: A retrospective study in the SEER database and China cohort","authors":"Bo Huang ,&nbsp;Wei-Dong Wang ,&nbsp;Fang-Cai Wu ,&nbsp;Xiao-Mei Wang ,&nbsp;Bu-Qing Shao ,&nbsp;Ying-Miao Lin ,&nbsp;Guo-Xing Zheng ,&nbsp;Gui-Qiang Li ,&nbsp;Can-Tong Liu ,&nbsp;Yi-Wei Xu ,&nbsp;Xin-Jia Wang","doi":"10.1016/j.jbo.2025.100683","DOIUrl":"10.1016/j.jbo.2025.100683","url":null,"abstract":"<div><h3>Purpose</h3><div>Esophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor worldwide, and individuals with ESCC and bone metastasis (BM) often face a challenging prognosis. Our objective was to identify the risk and prognostic factors associated with BM in patients with ESCC and develop a nomogram for predicting Cancer-Specific Survival (CSS) which following the occurrence of BM.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of data pertaining to ESCC patients with BM registered in the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015, as well as those treated at a Chinese institution from 2006 to 2020. Significant prognostic factors for CSS were assessed through univariate and multivariate Cox regression analyses. Subsequently, a nomogram was developed utilizing the SEER database and externally validated using real-world evidence from a Chinese cohort.</div></div><div><h3>Results</h3><div>A total of 266 patients from the SEER database and 168 patients from the Chinese cohort were included in the analysis. In the SEER cohort, multivariate analysis indicated that chemotherapy, radiotherapy, liver metastasis, brain metastasis, and sex were independent prognostic factors for ESCC with BM. The prognostic nomogram demonstrated areas under the ROC curve (AUCs) of 0.823, 0.796, and 0.800, respectively, for predicting 3-, 6-, and 12-month CSS. In the Chinese validation cohort, the nomogram exhibited acceptable discrimination (AUCs: 0.822, 0.763, and 0.727) and calibration ability.</div></div><div><h3>Conclusion</h3><div>The study developed a prognostic nomogram to predict CSS in ESCC patients with BM, which can help clinicians assess survival and make individualized treatment decisions.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100683"},"PeriodicalIF":3.4,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in bone Metastases: A systematic review in guideline adherence of 92 studies","authors":"Lotte R. van der Linden ,&nbsp;Ioannis Vavliakis ,&nbsp;Tom M. de Groot ,&nbsp;Paul C. Jutte ,&nbsp;Job N. Doornberg ,&nbsp;Santiago A. Lozano-Calderon ,&nbsp;Olivier Q. Groot","doi":"10.1016/j.jbo.2025.100682","DOIUrl":"10.1016/j.jbo.2025.100682","url":null,"abstract":"<div><h3>Background</h3><div>The last decade has witnessed a surge in artificial intelligence (AI). With bone metastases becoming more prevalent, there is an increasing call for personalized treatment options, a domain where AI can greatly contribute. However, integrating AI into clinical settings has proven to be difficult. Therefore, we aimed to provide an overview of AI modalities for treating bone metastases and recommend implementation-worthy models based on TRIPOD, CLAIM, and UPM scores.</div></div><div><h3>Methods</h3><div>This systematic review included 92 studies on AI models in bone metastases between 2008 and 2024. Using three assessment tools we provided a reliable foundation for recommending AI modalities fit for clinical use (TRIPOD or CLAIM ≥ 70 % and UPM score ≥ 10).</div></div><div><h3>Results</h3><div>Most models focused on survival prediction (44/92;48%), followed by imaging studies (37/92;40%). Median TRIPOD completeness was 70% (IQR 64–81%), CLAIM completeness was 57% (IQR 48–67%), and UPM score was 7 (IQR 5–9). In total, 10% (9/92) AI modalities were deemed fit for clinical use.</div></div><div><h3>Conclusion</h3><div>Transparent reporting, utilizing the aforementioned three evaluation tools, is essential for effectively integrating AI models into clinical practice, as currently, only 10% of AI models for bone metastases are deemed fit for clinical use. Such transparency ensures that both patients and clinicians can benefit from clinically useful AI models, potentially enhancing AI-driven personalized cancer treatment.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100682"},"PeriodicalIF":3.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}